M&A Deal Summary |
|
|---|---|
| Date | 2018-03-11 |
| Target | StageBio |
| Sector | Life Science |
| Buyer(s) | Ampersand Capital Partners |
| Deal Type | Buyout (LBO, MBO, MBI) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Growth Capital Firm |
|---|---|
| Founded | 1988 |
| PE ASSETS | 3.0B USD |
| Size | Large |
| Type | Sector Focused |
Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 43 of 84 |
| Sector (Life Science) | 17 of 43 |
| Type (Buyout (LBO, MBO, MBI)) | 17 of 23 |
| State (Virginia) | 1 of 1 |
| Country (United States) | 43 of 69 |
| Year (2018) | 2 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-02-08 |
Corpus Medical
Campbell, California, United States Corpus Medical, Inc. is a provider of high-quality consulting and manufacturing services for the development and commercialization of innovative intervention medical devices. Corpus Medical specializes in catheter technologies, assembly of fully packaged devices and medical implants. Corpus Medical was founded in 2009 and is based in Campbell, California. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-03-20 |
Nexcelom Bioscience
Lawrence, Massachusetts, United States Nexcelom Bioscience is a designer, manufacturer, and marketer of innovative Cellometer and Celigo image cytometry products designed for cell analysis in life science and biomedical research. Nexcelom Bioscience was founded in 2003 and is based in Lawrence, Massachusetts. |
Buy | - |
